# A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

> **NCT03482011** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 530 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Mirikizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03482011
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-24
- **Primary completion:** 2019-03-21
- **Final completion:** 2020-01-16
- **Target enrollment:** 530 (ACTUAL)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03482011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03482011, "A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03482011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*